Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00032435 | Homocysteine Study (HOST) | PHASE3 | COMPLETED | 2,003 | — | — | May 1, 2001 | Sep 1, 2006 | Oct 15, 2010 | 37 | United States, Puerto Rico |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | PAL-40 Active |
| 2 | PLACEBO_COMPARATOR | PAL-40 Placebo |
| Name | Type | Description |
|---|---|---|
| PAL-40 Active | DRUG | - |
| PAL-40 Placebo | DRUG | - |
Inclusion Criteria: Patients will be screened by their plasma homocysteine concentration. They must have a level of at least 15 mM/L to be enrolled in the study. Patients will be excluded by any of the following criteria: age less than 21 years, expected life span less than 6 months, pregnancy, me...